This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coleman, A. Articles by Lugo, T. G. Search for Related Content PubMed PubMed Citation Articles by Coleman, A. Articles by Lugo, T. G.

Distinct Deletions of Chromosome 9p Associated with Melanoma versus Glioma, Lung Cancer, and Leukemia¹

Division of Biomedical Sciences, University of California, Riverside, California 92521 [A. C., G. R., T. G. L.]; Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [J. W. F, D. E. H.]; Department of Medicine, University of California, San Diego, California 92093 [T. N.]; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 [O. L O.]

² To whom requests for reprints should be addressed.

Deletions of DNA on chromosome 9p21–22 are frequently observed in cells derived from melanomas, gliomas, non-small cell lung cancers, and acute lymphoblastic leukemia. The minimal deletion shared by the latter three cancers extends from the interferon- locus towards the centromere; its centromeric end is flanked by the gene encoding methylthioadenosine phosphorylase. We have determined that the telomeric end of the minimal homozygous deletion shared by two melanoma cell lines does not include the methylthioadenosine phosphorylase locus. Thus, a distinct region of DNA is lost in melanoma. The physical size of this region remains to be defined precisely, but it may extend over several million base pairs.

¹ This work was supported in part by Grants CA56910 (T. G. L.), HG00297 (D. E. H.), CA17575 (D. E. H.), and CA08985 (J. W. F.) from the Cancer Research Coordinating Committee of the University of California and from the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/ 7/93. Accepted 11/24/93.

This article has been cited by other articles:

				S. A. Christopher, P. Diegelman, C. W. Porter, and W. D. Kruger Methylthioadenosine Phosphorylase, a Gene Frequently Codeleted with p16cdkN2a/ARF, Acts as a Tumor Suppressor in a Breast Cancer Cell Line Cancer Res., November 15, 2002; 62(22): 6639 - 6644. [Abstract] [Full Text] [PDF]

				H. Momoi, H. Okabe, T. Kamikawa, S. Satoh, I. Ikai, M. Yamamoto, A. Nakagawara, Y. Shimahara, Y. Yamaoka, and M. Fukumoto Comprehensive Allelotyping of Human Intrahepatic Cholangiocarcinoma Clin. Cancer Res., September 1, 2001; 7(9): 2648 - 2655. [Abstract] [Full Text] [PDF]

				C. PORTWINE, J. LEES, S. VERSELIS, F. P LI, and D. MALKIN Absence of germline p16INK4a alterations in p53 wild type Li-Fraumeni syndrome families J. Med. Genet., August 1, 2000; 37(8): 13e - 13. [Full Text]

				P Cairns, L Mao, A Merlo, D. Lee, D Schwab, Y Eby, K Tokino, P van der Riet, J. Blaugrund, and D Sidransky Rates of p16 (MTS1) mutations in primary tumors with 9p loss Science, July 15, 1994; 265(5170): 415 - 417. [PDF]

				A. Kamb Role of a Cell Cycle Regulator in Hereditary and Sporadic Cancer Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 39 - 47. [Abstract] [PDF]